Sangamo Therapeutics shares jumped about 33% Monday as the company prepared to move from Nasdaq to the OTCQB Venture Market following a delisting notice over its sub-$1 share price. Nasdaq is set to suspend trading in SGMO on May 5. Sangamo said it will appeal but expects trading to shift regardless. The company is seeking new funding and continues talks on partnerships and its Fabry disease gene therapy. The post Sangamo Stock Jumps Before Nasd…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.